In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1658-1667

  Hong, Haizheng ^a   Su, Hong ^a   Ma, Li ^a   Yao, Ming ^a   Iyer, Ramaswamy A ^a   Humphreys, W Griffith ^a   Christopher, Lisa J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; 4 AMINO 1 [[4 [(3 METHOXYPHENYL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 5 YL]METHYL] 3 PIPERIDINOL; BMS 690514; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B4; GLUCURONOSYLTRANSFERASE 2B7; KETOCONAZOLE; MONTELUKAST; ORPHENADRINE; QUINIDINE; SULFAPHENAZOLE; TRANYLCYPROMINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

AEROBIC METABOLISM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; NADP; PIPERIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRIAZINES; URIDINE DIPHOSPHATE GLUCURONIC ACID;

EID: 80051967794     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039776     Document Type: Article

References (29)

1. Bahleda R., Felip E., Herbst R.S., Hanna N.H., Laurie S.A., Shepherd F.A., Armand J.P., Sweeney C.J., Calvo-Aller E, and Soria J.C. (2008) Phase I multicenter trial of BMS-690514: safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 26 (15 Suppl):abstr 2564.
2. Bahleda R., Soria J., Harbison C., Park J., E. Felip, Hanna N., Laurie S.A., Armand J., Shepherd FA, and Herbst R. (2009) Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 27 (15 Suppl):abstr 8098.
3. Barre L., Fournel-Gigleux S., Finel M., Netter P., Magdalou J, and Ouzzine M. (2007) Substrate specificity of the human UDP- Glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33. FEBS J 274:1256-1264.
4. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., et al. (2003) The conduct of in vitro and in vivo drug- Drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469. (Pubitemid 36506147)
5. 14C]BMS-690514, an ErbB/vascula endothelial growth factor receptor inhibitor, after oral administration to humans. Drug Metab Dispos 38:2049-2059.
6. Court M.H. (2005) Isoform- Selective probe substrates for in vitro studies of human UDPglucuronosyltransferases. Methods Enzymol 400:104-116.
7. Hong H., Caceres-Cortes J., Su H., Huang X., Roongta V., Bonacorsi S. Jr, Hong Y., Tian Y., Iyer R.A., Humphreys W.G., et al. (2011) Mechanistic studies on a P450- Mediated rearrangement of BMS- Mediated rearrangement of BMS690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine. Chem Res Toxicol 24:125-134.
8. 14C]BMS-690514 after oral administration to rats, rabbits, and dogs. Drug Metab Dispos 38:1189-1201.
9. Hurst S., Williams JA, and Hansel S. (2007) Reaction phenotyping, in Drug Metabolism in Drug Design and Development (Zhang D, Zhu M, and Humphreys GW eds) pp 477-510, John Wiley & Sons, Inc., Hoboken, NJ.
10. Kiang T.K., Ensom MH, and Chang T.K. (2005) UDP- Glucuronosyltransferases and clinical drug- Glucuronosyltransferases and clinical drugDrug interactions. Pharmacol Ther 106:97-132.
11. Krishnaswamy S., Duan S.X., Von Moltke L.L., Greenblatt DJ, and Court M.H. (2003) Validation of serotonin (5- Hydroxtryptamine) as an in vitro substrate probe for human UDP- Hydroxtryptamine) as an in vitro substrate probe for human UDPGlucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133-139. (Pubitemid 36735267)
12. Marathe P., Tang Y., Sleczka B., Rodrigues D., Gavai A., Wong T., Christopher L, and Zhang H. (2010) Preclinical pharmacokinetics and in vitro metabolism of BMS- 690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci 99:3579-3593.
13. Nassar A.E., King I., Paris B.L., Haupt L., Ndikum-Moffor F., Campbell R., Usuki E., Skibbe J., Brobst D., Ogilvie B.W., et al. (2009) An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes. Drug Metab Dispos 37:1922-1930.
14. Ogilvie B.W., Usuki E., Yerino P, and Parkinson A. (2008) In vitro approaches for studying the inhibition of drug- Metabolizing enzymes and identifying the drug- Metabolizing enzymes and identifying the drugMetabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450, in Drug-Drug Interactions: Drugs and Pharmaceutical Sciences (Rodrigues AD ed) pp 231-358, Informa Healthcare, New York.
15. Remmel R., Nagar S, and Argikar U. (2007) Conjugative metabolism of drugs, in Drug Metabolism in Drug Design and Development (Zhang D, Zhu M, and Humphreys WG eds) pp 37-88, John Wiley & Sons, Inc., Hoboken, NJ.
16. Rodrigues A.D. (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA- Expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
17. Saeki M., Saito Y., Jinno H., Tanaka-Kagawa T., Ohno A., Ozawa S., Ueno K., Kamakura S., Kamatani N., Komamura K., et al. (2004) Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048-1054. (Pubitemid 39096067)
18. Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin HV, and Shou M. (2000) Assessment of specificity of eight chemical inhibitors using cDNA- Expressed cytochromes P450. Xenobiotica 30:327-343. (Pubitemid 30251243)
19. Sinz M., Wallace G, and Sahi J. (2008) Current industrial practices in assessing CYP450 enzyme induction: Preclinical and clinical. Aaps J 10:391-400.
20. Tabernero J. (2007) The role of VEGF and EGFR inhibition: implications for combining anti- VEGF and anti- VEGF and antiEGFR agents. Mol Cancer Res 5:203-220.
21. Tortora G., Ciardiello F, and Gasparini G. (2008) Combined targeting of EGFR- Dependent and VEGF- Dependent and VEGFDependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5:521-530.
22. Uchaipichat V., Mackenzie P.I., Elliot DJ, and Miners J.O. (2006a) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDPglucuronosyltransferases. Drug Metab Dispos 34:449-456.
23. Uchaipichat V., Winner L.K., Mackenzie P.I., Elliot D.J., Williams JA, and Miners J.O. (2006b) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: The effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
24. Wang H and LeCluyse E.L. (2003) Role of orphan nuclear receptors in the regulation of drug- Metabolising enzymes. Clin Pharmacokinet 42:1331-1357. (Pubitemid 38045840)
25. Wortelboer H.M., De Kruif C.A., Van Iersel A.A., Falke H.E., Noordhoek J, and Blaauboer B.J. (1990) The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochem Pharmacol 40:2525-2534.
26. Yamanaka H., Nakajima M., Katoh M., Kanoh A., Tamura O., Ishibashi H, and Yokoi T. (2005) Trans- 3′- 3′Hydroxycotinine O- and N- 3′Hydroxycotinine OAnd NGlucuronidations in human liver microsomes. Drug Metab Dispos 33:23-30. (Pubitemid 40023510)
27. Yao M., Zhu M., Sinz M.W., Zhang H., Humphreys W.G., Rodrigues AD, and Dai R. (2007) Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96- Well microplate incubation format and LC- Well microplate incubation format and LCMS/MS analysis. J Pharm Biomed Anal 44:211-223. (Pubitemid 46551606)
28. Zhang D., Zhao W., Roongta V.A., Mitroka J.G., Klunk LJ, and Zhu M. (2004) Amide N- Glucuronidation of MaxiPost catalyzed by UDP- Glucuronidation of MaxiPost catalyzed by UDPGlucuronosyltransferase 2B7 in humans. Drug Metab Dispos 32:545-551. (Pubitemid 38535033)
29. Zhang H., Sinz MW, and Rodrigues A.D. (2007) Metabolism- Mediated drug- Mediated drugDrug interactions, in Drug Metabolism in Drug Design and Development (Zhang D, Zhu M, and Humphreys WG eds) pp 113-136, John Willey & Sons, Inc., Hoboken, NJ.